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LFASevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infectedmore than 8million people world-
wide, becoming a pandemic. Detecting antibodies against SARS-CoV-2 is of utmost importance and a good indi-
cator of exposure and circulation of the virus within the general population. Two serological tools based on a
double recognition assay [enzyme-linked immunosorbent assay (DR-ELISA) and lateral flow assay (DR-LFA)]
to detect total antibodies to SARS-CoV-2 have been developed based on the recombinant nucleocapsid protein.
A total of 1065 serum samples, including positive for COVID-19 and negative samples from healthy donors or in-
fected with other respiratory pathogens, were analyzed. The results showed values of sensitivity between 91.2%
and 100%, and specificity of 100% and 98.2% for DR-LFA and DR-ELISA, respectively. No cross-reactivity against
seasonal coronavirus (HCoV-NL63, HCoV-229E, HCoV-HKU1, HCoV-OC43)was found. These results demonstrate
the importance of serology as a complementary tool to polymerase chain reaction for follow-up of recovered pa-
tients and identification of asymptomatic individuals.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In December 2019, a novel coronavirus of animal origin [the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] emerged
in the city of Wuhan, China, with the ability for human-to-human
transmission (Zhu et al., 2020). The associated disease, now named
COVID-19, spread rapidly all over the world and was declared a pan-
demic by theWorld Health Organization (WHO) onMarch 11, 2020. In-
fection due to SARS-CoV-2 induces high rates of morbidity and
mortality as described by the WHO (2020). A significant concern is
how rapidly the virus spreads due in major part to the high number of
asymptomatically infected individuals which could be an important
source of viral dissemination (Bai et al., 2020; Du et al., 2020; Hu et al.,
2020). Themain preventiveways to avoid the spread of the virus are hy-
giene measures together with keeping social distance, as there are no+34-914-08-75-98.
nc. This is an open access article undvaccine available, neither efficient treatment. Serological studies can
be used to collect epidemiological information on the prevalence of
SARS-CoV-2. Moreover, in cases of COVID-19 not detected by reverse-
transcription polymerase chain reaction (RT-PCR), the serological as-
says should be considered as a supplementary diagnostic tool, especially
from the secondweek of illness when the sensitivity of the current mo-
lecular tests decreases (Pan et al., 2020; Zou et al., 2020). Therefore, the
aim of the presentworkwas the development of serological tools to de-
termine the presence of antibodies against SARS-CoV-2 in the popula-
tion as an indicator of an ongoing or previous infection.
Aswithmanyother coronaviruses, one of themain structural proteins
of SARS-CoV-2 is the nucleocapsid (N) protein. The N protein shows high
immunogenic activity and is abundantly expressed during infection (Che
et al., 2004; Meyer et al., 2014; Narayanan et al., 2003). These features
make theN protein a potential target for serodiagnosis of SARS-CoV-2 in-
fection. To date, some diagnosticmethods have been developed based on
the N protein, although validated methods are still lacking to better un-
derstand the epidemiology of SARS-CoV-2. In the current study, a doubleer the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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oped to determine the presence of immunoglobulins of different classes
(IgG, IgM and IgA) to SARS-CoV-2 in human serum to support the diag-
nosis of COVID-19. In parallel with this screening tool, a point-of-care
test, based also on a double recognition format [a double recognition lat-
eral flow assay (DR-LFA)] and using the N protein as the target antigen,
was produced to be used immediately and on site when there is suspi-
cion for infection. A double recognition assay is based on the use of the
same protein (in this case, the N protein) as the target antigen and detec-
tion molecule, using the principle that antibodies possess multiple anti-
gen binding regions (2 for IgG, 4 for IgA, and 10 for IgM), allowing their
binding to both the target and detection antigen. Double recognition
tests have the advantage that they screen for all SARS-CoV-2 antibodies,
regardless if it is IgA, IgG, or IgM.
To carry out this study, a total of 1065 samples were analyzed with
380 samples from positive patients to COVID-19 and 685 negative sam-
ples collected before 2019 or from patients negative to COVID-19.
Finally, a cohort of samples from patients infected with common-cold
coronavirus or respiratory pathogens that could potentially cross-react
with SARS-CoV-2 was included in the study.
The results shown in this paper reinforce the potential utility of sero-
logical testing as a complementary tool for interpretation of results in
different scenarios of infection with SARS-CoV-2, including the identifi-
cation of asymptomatic individuals.
2. Materials and methods
2.1. Serum samples
A total of 1065 human serum samples were used in this study.
Eighty-seven serum samples were provided by the Hospital General
Universitario Gregorio Marañón in Madrid (Spain), 140 serum samples
by the Instituto de Salud Carlos III (Madrid, Spain), 665 serum samples
from the “Program of Surveillance and Early Detection Program of
COVID19 in essential services personnel of the city of Madrid” given
by the Institute of Public Health of the Madrid City Council (Spain),
109 serum samples by the Amsterdam University Medical Center in
Amsterdam (the Netherlands), and 64 serum samples already available
in the lab from a previous European project, RespViruses (EU FP6-2005-
LIFESCHEALTH-7). The samples were classified as follows: 163 serum
samples of patients positive to COVID-19 by PCR (all the PCRs described
in this study were RT-PCRs done in respiratory material) and confirmed
by a commercial assay [NovaLisa® SARS-CoV-2 IgG and IgM ELISAs
(Novatec) or 2019-nCoV IgG/IgM Rapid Test (T&D Diagnostics Canada)]
, 43 serum samples of patients positive to COVID-19 by PCR but negative
in the serological assays, 174 serum samples of patients negative to
COVID-19 by PCR but positive in a commercial serological assay, 452
serum samples of patients negative to COVID-19 both by PCR and sero-
logical assay, and 233 negative sera collected before 2019. A summary
of these data is shown in Table 1.
A collection of sera positive to other infectious diseases which can
provoke pneumonia (5 sera positive to Chlamydia trachomatis, 17 posi-
tive toMycoplasma pneumoniae, and 21 to Legionella pneumophila) was
tested and classified by the Department of Serology of the Spanish Na-
tional Center of Microbiology and was included in our study.Table 1






Samples prior 2019 233
Total 1065The 64 samples from the RespViruses project were collected from
blood donors and people requesting serological tests and other virological
investigations at theUniversityHospital Bonn, and62were foundpositive
to human respiratory syncytial virus (hRSV) in different assays (Sastre
et al., 2010).
Finally, the collection provided by the Amsterdam University Medical
Center included a total of 20 serum samples from the Amsterdam Cohort
Studies onhuman immunodeficiency virus infection andAIDS (vanBilsen
et al., 2020). The sera were obtained shortly (within 6 months) after in-
fection by a seasonal Alphacoronavirus (HCoV-NL63 or HCoV-229E) or a
seasonal Betacoronavirus (HCoV-HKU1 or HCoV-OC43) and contained
high concentrations of antibodies to these common-cold coronaviruses.
For all the human serum samples collected, the participation was
voluntary and without incentive. Formal agreements with the institu-
tions providing the serum samples or written informed consent of
each participant at enrollment was obtained.
2.2. Production of SARS-CoV-2 nucleocapsid protein
The cDNA encoding for the full-length nucleocapsid protein of the
SARS-CoV-2 (GenBank accession NC_045512) was kindly provided by
Dr. Volker Thiel. The forward primer N (5′-TCT GAT AAT GGA CCC CAA
AAT C-3′) and reverse primer N (5′-TTA GGC CTG AGT TGA GTC AGC-
3′) were used to amplify this gene. The N protein was cloned in the
pCR™8/GW/TOPO™ and subsequently in the Gateway™ pDEST™17Vec-
tor (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA), carrying a
polyhistidine tag, according to the manufacturer's instructions. Resulting
plasmid was verified by sequence analysis and used to transform BL21-
AI™One Shot™ (Invitrogen; Thermo Fisher Scientific, Inc.). TheNprotein
was produced in Escherichia coli; an overnight culture was grown in ly-
sogeny broth medium, supplemented with ampicillin (100 μg/mL) and
incubated at 37 °C, 220 rpm. The overnight culture was diluted in fresh
medium and incubated at 37 °C until reaching an optical density at
600 nm between 0.6 and 0.8. The culture was then induced with arabi-
nose 0.2% and incubated overnight at 18 °C, with shaking at 220 rpm.
The cells were harvested by centrifugation and resuspended in lysis
buffer [300 mM NaCl; 20 mM Tris–HCl, pH 7.4; 20 mM imidazole;
1mMMgCl2; 0.1% Triton X-100; 1mg/mL lysozyme; 1 tablet cOmplete™,
EDTA-free Protease Inhibitor Cocktail (Roche Applied Science)]. Finally,
the N protein was purified using High-Density Metal Free resin
(Agarose Bead Technologies) coupled to nickel according to the
manufacturer's instructions. Protein gel electrophoresis followed
by Coomassie staining was used to assess the purity and molecular
size of the N protein.
The SARS-CoV-2 N proteinwas labeledwith peroxidase according to
the method described by Nakane and Kawaoi (1974) to be used as de-
tector molecule in the DR-ELISA described below.
2.3. DR-ELISA (INgezim COVID 19 DR)
A DR-ELISA was developed as previously described (Venteo et al.,
2012). Briefly, the N protein was used to coat 96-well plates and incu-
bated overnight at 4 °C in carbonate buffer, pH 9.6. After washing the
wells with phosphate buffered saline pH 7.4 with 0.05% Tween 20
(PBST), a blocking step was performedwith StabilZyme® SELECT Stabi-
lizer (SurModics, Inc.) for 1 h at room temperature (RT). The plate was
incubated with serum samples diluted 1:5 in PBST with 2.5% fetal
bovine serum (Gibco; Thermo Fisher Scientific, Inc.) for 30 min at RT.
Duplicates of positive (rabbit polyclonal antibody to N protein of
SARS-CoV-2 produced in-house) and negative (dilution buffer) controls
were included in each plate. The wells were washed as described above
and incubated with the HRP-conjugated N protein for 30 min at RT. Fi-
nally, after a washing step, the plate was incubated for 15 min with
the substrate (TMB-MAX, Neogen Corporation), and the reaction was
stopped by addition of 0.5 M sulfuric acid. The absorbance was
3A.CR. Hoste et al. / Diagnostic Microbiology and Infectious Disease 98 (2020) 115167measured at 450 nm using a SpectraMax M5 plate reader (Molecular
Devices, LLC).2.4. DR-LFA (INgezim COVID 19 CROM)
2.4.1. Capture reagents
RecombinantN proteinwas diluted to 0.2mg/mL in 20mMTris–HCl
buffer at pH 8.5 to be used as the test line capture reagent. As control
line capture reagent, a monoclonal antibody against the control protein
(Probumin® Bovine Serum Albumin, Merck Millipore) at 1 mg/mL was
used. Both reagents were dispensed in 2 parallel lines on nitrocellulose
membrane (HF120,MerckMillipore). After drying for 5min at 45 °C, the
membranes were sealed and stored at room temperature.Fig. 1. Polyacrylamide gel electrophoresis of SARS-CoV-2 N protein expressed and purified
from bacterial cultures, and visualized following staining with Coomassie brilliant blue.
From left to right: uninduced culture (lane 1), induced culture (lane 2), N protein before
purification (lane 3), and N protein after purification by immobilized metal affinity2.4.2. Detector reagents
Black latex beads (Merck Millipore) were activated with
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
and N-hydroxysuccinimide and then coupled to N protein at a sur-
face concentration of 1mg/m2, and blue latex beads were conjugated
with the control protein.
To prepare the conjugate solution, theN-latex and control-latex par-
ticleswere diluted at a concentration of 0.15% each in a 25-mMTris–HCl
pH 9.5 buffer. Themixture was dispensed onto the conjugate pad, dried
for 30 min at 45 °C, and stored at room temperature.chromatography (lane 4, MW: 46.5 kDa).2.4.3. Preparation of chromatographic strips
To assemble the 30-cm master card, nitrocellulose membrane,
conjugate pad, sample pad (Cytosep 1662, Ahlstrom-Munksjö), and
wicking pad were pasted on a plastic backing with adhesive and cov-
ered with a protector film. The master card was then cut into strips of
4.2-mm width.2.4.4. Test procedure
The test was designed to be used with serum, plasma, and blood
samples.
Twenty microliters of blood or 10 mL of serum/plasma was applied
to the sample pad followed by 110 μL of running buffer (Tris–HCl
pH 7.5, NaCl, casein, and NaN3). Results were interpreted 10 min after
running buffer addition. A scale of the intensity of the signal of the test
line from 1 to 10 was used in order to give a semiquantitative value
for statistical purposes.2.5. Statistical analysis
Data were statistically analyzed by a receiver–operator characteris-
tics (ROC) curve analysis using the MedCalc® 10 software to establish
the optimal cutoff value for each assay. Prior to the analyses, the sam-
ples were classified into positive or negative by PCR or by other com-
mercial serological assays. Using the same software, Fisher's exact test
was performed to determine the statistical dependence between the 2
assays developed.3. Results
3.1. Expression of the SARS-CoV-2 N protein
The complete SARS-CoV-2Nproteinwas cloned in the pDEST17 vec-
tor, expressed in E. coli, and further purified by immobilizedmetal affin-
ity chromatography. The highly purified N protein was analyzed by gel
electrophoresis followed by Coomassie staining. A band of the expected
molecularmass of the N protein (around 45 kDa)was observed (Fig. 1).3.2. Validation of the newly developed tools: DR-ELISA and DR-LFA with
samples from positive patients to COVID-19 and healthy donors
DR-ELISA and DR-LFA were developed based on the N protein of
SARS-CoV-2. The DR-ELISA's and DR-LFA's conditions were assessed to
obtain the optimal conditions for detection of total antibodies in the
sera and blood against SARS-CoV-2.
After optimization of each assay (data not shown), a total of 1065
sampleswere tested in theDR-ELISA, classified as described in “Material
and Methods.” To determine the performance characteristics of the
newly developed DR-ELISA, an ROC analysis was performed. Since
there is currently no serological gold standard, the samples were
considered positive or negative according to the results obtained by
PCR (in respiratory material) and a commercial serological assay (in
serum). Moreover, the group of serum samples collected before 2019
was considered true-negative samples. The correlation between the re-
sults obtained in the DR-ELISA and the classification of the samples as
positive (positive in PCR and serological assay) and negative (negative
in PCR and serological assay or collected prior 2019) was determined.
To calculate the cutoff of the assay, the sample to positive control (S/P)
ratio was calculated using: S=P ¼ test sample−mean negative controlmean positive control−mean negative control:
Based on this S/P value, samples were considered negativewhen the
S/P ratio was under 5.6 and positive when its S/P ratio was equal to or
above 5.6. With these values, the diagnostic sensitivity of the DR-
ELISAwas 100%with a 95% confidence interval (97.7–100%), and the di-
agnostic specificity was 98.2% with a 95% confidence interval (97–
99.1%) (Fig. 2A).
An ROC analysis was also performed to determine the performance
characteristics of the DR-LFA and displayed in an interactive dot plot di-
agram (Fig. 2B). A lower number of samples were tested in the DR-LFA:
113 serum samples positive by PCR and a serological assay, 14 negative
by PCR and a serological assay, and 120 serum samples collected prior
2019. The diagnostic sensitivity of the DR-LFA was 91.2% with a 95%
confidence interval (84.7–95.7%), and the diagnostic specificity was
100% with a 95% confidence interval (97.3–100%).
For both assays developed, the null hypothesis was the area under
the ROC curve is equal to 0.5. The P values obtained were 0.0001;
Fig. 2. Validation of the DR-ELISA and DR-LFA. Dot plot diagrams where each dot
represents an individual sample: results obtained for DR-ELISA (A) and DR-LFA (B). The
horizontal solid line corresponds to the cutoff values in each assay, according to the
MedCalc® 10 software. X-axis shows the positive (1) or negative (0) classification of
samples according to the PCR and serological assay, and Y-axis shows S/P ratio and
intensity obtained in the DR-ELISA and DR-LFA, respectively.
4 A.CR. Hoste et al. / Diagnostic Microbiology and Infectious Disease 98 (2020) 115167therefore, there is evidence that the 2 assays developed can distinguish
between the positive and negative samples tested.
Finally, a comparison was done between the DR-ELISA and DR-LFA
with the samples tested in both assays. Out of the 114 positive samples
in the DR-ELISA, 92.3% were positive in the DR-LFA, and out of the 133
negative samples tested in the DR-ELISA, 100% were also negative in
the DR-LFA. Using the MedCalc® 10 software, Fisher's exact test was
performed to examine the relation between the results obtained in
the DR-ELISA and in the DR-LFA. The null hypothesis being that the var-
iables are independent, P< 0.000000001,meaning that there is a signif-
icant relationship between the 2 assays. The comparison between the 2
techniques is summarized in Table 2.Table 2




Positive 106 0 106
Negative 8 133 141
Total 114 133 2473.3. Cross-reactivity by antibodies directed to common-cold Alpha- and
Betacoronavirus and other respiratory pathogens
To fully validate the DR-ELISA and DR-LFA, the potential cross-
reactivity by antibodies induced by infectionwith seasonal coronaviruses
(HCoV-NL63, HCoV-229E, HCoV-HKU1, and HCoV-OC43) was examined
by both assays.Moreover, the assayswere testedwith sera containing an-
tibodies to pathogens that can induce pneumonia in infected patients
such as C. trachomatis,M. pneumoniae, L. pneumophila, and hRSV, the lat-
ter only tested in the DR-ELISA. Neither of the assays showed cross-reac-
tivity against any of the other coronaviruses, neither any other respiratory
pathogen. We found one false-positive signal in the DR-ELISA to M.
pneumoniae (see Table 3).
4. Discussion
For the new emerging virus SARS-CoV-2, the routinely used tech-
nique for testing patients is the RT-PCR, which detects the RNA of the
virus at early stages of the infection (Zou et al., 2020). Fully validated se-
rological tests are still missing as many of the commercial serological
tests currently available for SARS-CoV-2 are poorly validated or display
low sensitivity or specificity (Krüttgen et al., 2020). In order to deter-
mine the prevalence of antibodies in the population and to complement
the nucleic acid detection assays, especially at later days after the onset
of the symptoms, serological assays are required (Meyer et al., 2014).
Detection of antibodies is the most valuable indicator of the immune
status of a person, identifying patients that have had COVID-19 infection
and providing more accurate data related to risk of infection.
In the present study, we developed 2 serological assays using the re-
combinant N protein of SARS-CoV-2 as the target antigen: a DR-ELISA
which is aimed to be used for screening of large numbers of samples
and could be used in epidemiological studies and a DR-LFA for point-
of-care testing of individual patients, which could be used by physicians
without any laboratory setting required. The double recognition
method was previously used by our laboratory to develop a DR-ELISA
and 2DR-LFAs for detection of antibodies to other infectious diseases af-
fecting swine (Fresco-Taboada et al., 2019; Sastre et al., 2016; Venteo
et al., 2012).
A panel of standardized samples was included in the study to deter-
mine the performance characteristics of the tests. Positive samples from
COVID-19 patients with a range of clinical presentations at multiple
time points after onset of symptoms were analyzed to determine the
sensitivity. Pre–COVID-19 outbreak samples and samples with antibod-
ies to other respiratory pathogens were used to determine the specific-
ity. The diagnostic sensitivity of the assays was 100% and 91.2% for the
DR-ELISA and DR-LFA, respectively. The sensitivity of the DR-LFA was
lower than that of the DR-ELISA, as it has been described in other
cases (Parolo et al., 2013). The requirements of each assay are different,
as the DR-LFA can be applied as a point-of-care test, whereas the
DR-ELISA needs to be done in a laboratory by qualified technicians.
Moreover, while the DR-LFA takes 10 min to give 1 result, the
DR-ELISA takes 75 min to analyze 92 samples. Out of the PCR+/Table 3
Cross-reactivity with other respiratory pathogens.
DR-ELISA DR-LFA
Positive Negative Positive Negative
Alphacoronavirus (HCoV-NL63/
HCoV-229E) (n = 11)
0 11 0 11
Betacoronavirus
(HCoV-HKU1/HCoV-OC43) (n = 9)
0 9 0 9
Pneumovirus (hRSV) (n = 62) 0 62 ND ND
C. trachomatis (n = 5) 0 5 0 5
M. pneumoniae (n = 17) 1 16 0 17
L. pneumophila (n = 21) 0 21 0 21
ND = not determined.
5A.CR. Hoste et al. / Diagnostic Microbiology and Infectious Disease 98 (2020) 115167antibody− group from Table 1, a group of 14 serum samples from early
days postinfection, positive to COVID-19 by respiratory-PCR yet still
negative in the commercial serological assay (with seroconversion a
few days later), was also tested in our assays. Four of these sera were
positive in the DR-ELISA and 3 in the DR-LFA, indicating that the DR-
assays we developed are highly sensitive.
Regarding the specificity of the newly developed assays, we only
found 1 sample positive to M. pneumonia that gave a positive signal in
the DR-ELISA. Interestingly, no cross-reactivity by antibodies directed
to seasonal Alpha- or Betacoronavirus was observed in our DR assays,
in contrast with regular SARS-CoV-2 antibody tests that do sometimes
detect antibodies induced by HCoV-OC43 infection (Okba et al., 2020).
We tested samples from 452 individuals that were negative for the
virus in respiratory material (PCR) and also negative in serological as-
says, yet theywere collected in a high-risk group (personal communica-
tions). Eleven serum samples showed a positive signal in the DR-ELISA.
Five had a very high S/P (>30), and the others were foundwith lower S/
P (between 6 and 10). Three of the positives with high S/P were tested
also for confirmation purposes in the DR-LFA, and also in this test, the
samples showed positive signals. These results could indicate that our
tests can give false positives or that the patients had experienced a pre-
vious infection, yet this was not diagnosed by the commercial assays,
maybe not fully validated so far. The commercial tests used for classifi-
cation only detect IgG and IgM, and the samples could contain IgA anti-
bodies. This means these samples are considered negative in the
commercial tests, but positive in our DR assays that detect all Ig isotypes
(Béné et al., 2020).
The serological assays could be a great complementary tool to the
nucleic acid detection assays as, in this study, out of 626 samples with
a negative PCR in respiratory material, 174 serum samples could
diagnose a SARS-CoV-2 infection via serology (see Table 1). In these
174 patients, 123 were positive only to IgG, 23 were positive only to
IgM, and 28 were positive to IgG and IgM. An 89% correspondence
was found between the DR-ELISA and the commercial serological
assay for the 151 samples positive to IgG or positive to IgG and IgM,
but only 1 of the IgM positive was found positive in the DR-ELISA.
This could demonstrate the higher affinity of IgG compared to IgM
(Murphy et al., 2008), which could lead to lower specificity of serologi-
cal assays specifically targeting IgM.
Double recognition assays are sensitive tests, yet they also offer 2 ad-
ditional advantages. First, it is a multispecies test, detecting antibodies
in human serum but also in serum samples from other animal species
since it uses the target antigen as the detector molecule instead of
antispecies antibody, and secondly, it detects total antibodies in a
given sample. Unlike the antibody response usually observed in other
infectious diseases (first IgM followed by IgG), during COVID-19 infec-
tion, IgM and IgG antibody responses appear almost simultaneously
(Long et al., 2020; Sethuraman et al., 2020). Similar results were de-
scribed previously for SARS, where the IgM appeared at the same time
as the IgA and IgG (Meyer et al., 2014). This shows the importance of
having a test that detects total antibodies in serum.5. Conclusions
Using the N protein of the SARS-CoV-2 as the coating antigen and as
the enzyme-conjugated antigen instead of enzyme-conjugated second-
ary antibody provides a specific and sensitive serological assay for de-
tection of total antibodies to SARS-CoV-2. The 2 assays developed in
this study have been fully validated and received the CE marking.
They can be used as complementary tools to nucleic acid detection as-
says, in epidemiological studies for screening of large populations
(INgezim COVID 19 DR), and as point-of-care test (INgezim COVID 19
CROM), especially in later stages of the infection.Acknowledgments
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